文献速递类风湿关节炎

ACPA阴性类风湿关节炎中新自身抗体的发现

Novel autoantibodies identified in ACPA-negative rheumatoid arthritis.
PubMed 文献 · Ann Rheum Dis · 2021-01-15

研究基于蛋白微阵列技术在1011份血清中筛选并验证ACPA阴性RA的新自身抗体,发现9种新自身抗体,其中抗PTX3和抗DUSP11在ACPA阴性RA中阳性率分别为27.56%和31.80%,联合检测灵敏度38.00%、特异性88.72%。

要点

  • 抗PTX3和抗DUSP11在ACPA阴性RA中阳性率与ACPA阳性RA相似,显著高于健康对照和疾病对照。
  • 两抗体联合可将ACPA阴性RA诊断灵敏度提升至38.00%,特异性88.72%。
  • 两抗体诊断价值不受ACPA状态影响,可作为ACPA阴性RA的潜在生物标志物。

核心结论

  • 抗PTX3和抗DUSP11是ACPA阴性RA新识别的诊断生物标志物,联合检测可提高诊断灵敏度。

研究设计与样本

  • 收集1011份血清,包括559例RA(276例ACPA阳性、283例ACPA阴性)、239例疾病对照和213例健康对照,分两轮微阵列筛选及ELISA和Western blot验证。

主要发现

  • 两轮微阵列鉴定出9种新自身抗体,在ACPA阴性RA中阳性率17.93%-27.59%,特异性>90%。
  • 抗PTX3和抗DUSP11在ACPA阴性RA中阳性率分别为27.56%和31.80%,与ACPA阳性RA相似,显著高于健康对照(4.69%和2.35%)和疾病对照(10.04%和8.49%)(p<0.0001)。
  • 抗PTX3与抗DUSP11联合检测灵敏度38.00%,特异性88.72%,不受ACPA状态影响。

关键数值与推荐

  • 抗PTX3在ACPA阴性RA阳性率27.56%,健康对照4.69%,疾病对照10.04%。
  • 抗DUSP11在ACPA阴性RA阳性率31.80%,健康对照2.35%,疾病对照8.49%。
  • 联合检测灵敏度38.00%,特异性88.72%。

临床怎么用

  • 对于ACPA阴性疑似RA患者,可考虑检测抗PTX3和抗DUSP11以辅助诊断,联合检测可提高灵敏度。

局限性

  • 摘要未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Lack of effective biomarkers in anti-citrullinated protein antibody (ACPA)-negative rheumatoid arthritis (RA) impedes early diagnosis and treatment. This study aimed to identify novel autoantibodies in RA and verify their diagnostic values in ACPA-negative RA based on protein microarray technology. METHODS: A total of 1011 sera from 559 RA (276 ACPA-positive and 283 ACPA-negative), 239 disease controls (DCs) and 213 healthy controls (HCs) were collected and sampled on two sequential microarrays and ELISA and western blot (WB) detection, for novel autoantibodies discovery, validation and verification, respectively. The high-density protein microarray printed with a broad spectrum of recombinant human proteins was first employed to screen candidate autoantibodies, then focused microarrays composed of candidate autoantigens were used for validation, followed by ELISA and WB to verify the presence of the most promising candidates in ACPA-negative RA. RESULTS: Nine novel autoantibodies were identified by two sequential microarrays with positivity 17.93%-27.59% and specificities >90% in ACPA-negative RA. Among these, anti-PTX3 and anti-DUSP11 autoantibodies presented with the highest sensitivity and were consistently verified by ELISA and WB. Pooling samples of all cohorts, the positivities of anti-PTX3 and anti-DUSP11 in ACPA-negative RA were 27.56% and 31.80%, respectively, similar to those in ACPA-positive RA, and significantly higher than in HCs (4.69% and 2.35%) and DCs (10.04% and 8.49%) (p<0.0001). Combination of anti-PTX3 with anti-DUSP11 significantly increased the diagnostic sensitivity (38.00%) with specificity of 88.72%, regardless of ACPA status. CONCLUSION: Anti-PTX3 and anti-DUSP11 autoantibodies are newly identified biomarkers for diagnosis of ACPA-negative RA.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Li K, Mo W, Wu L, et al. Novel autoantibodies identified in ACPA-negative rheumatoid arthritis. Ann Rheum Dis. 2021. PMID: 33452006. doi:10.1136/annrheumdis-2020-218460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。